Paradigm Biopharmaceuticals Ltd has released a press release.
Paradigm 1HY22 Key Activity Highlights
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm treats first subjects in phase 3 trial of zilosul
- PAR reports postive topline results in heart failure model
- Preliminary Results from Phase 2 MPS I Study
- Paradigm CEO Paul Rennie to transition to Non-Exec Chairman
- Paradigm cleared for phase 3 trial by US FDA
Later from Paradigm Biopharmaceuticals
- S&P DJI Announces March 2022 Quarterly Rebalance
- Clarification of recent analyst report on Patent Protection
- FDA Grants Paradigm Fast Track Designation For OA
- Paradigm Doses First US Subjects under Phase 3 trial
- Paradigm Appoints Experienced US-Based CEO
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals